CATB
:NASDAQ

Add to watchlist
$0
Last updated:12/08/2021
CATB: NASDAQ
$0
Catabasis Pharmaceuticals Inc

Catabasis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics in the United States. The company's lead product candidate is QLS-215, a monoclonal antibody inhibitor of plasma kallikrein that is in preclinical development for the treatment of hereditary angioedema, a rare, debilitating and potentially life-threatening dis…

Dividend yield
-
P/E ratio
-
vs. 0.00x forward
Payout ratio
-
Yearly
CASH payout ratio
Last quarter
Become our supporter to unlock all data!
Stock volatility (Beta)
past 12 months
Become our supporter to unlock all data!
CATB dividends
Create free account to unlock
Company results
Qtr
Ann
Fundamentals
2017
2018
2019
2020
Net Income
Income minus expenses, depreciation, interest, taxes, and other expenses
Create free account to unlock
Cashflow
Sum up money going in and out company
Create free account to unlock
Total liabilities
All combined debts and obligations
Create free account to unlock
Company value
Market capitalization
Micro (109.52M)